Biocatalysis and biotechnology is a complex and rapidly moving field. Detailed structural and mechanistic information for exploring and engineering the properties of proteins, nucleic acids and other encoded molecules, has exploded over the last five years, particularly in the post human genome sequencing era (June, 2000). As such, it has been difficult for organizations, in particular key executives, even with their own internal biotechnology scientific businesses to keep adequately informed of the key changes and breakthroughs that are commercially important for their decision making. This should not be surprising, given the thousands of small startup companies covering a variety of biotech fields from mutagenesis, expression, transgenics, metabolic pathway engineering, bioinformatics, DNA arrays, drug screening and development and more.

To bridge the gap between science and commercialization, The Catalyst Group Resources is now offering an innovative "The Biotechnology Revolution: The BioPharmaceuticals Program" which provides the following services to subscribers:

• Two benchmark reports annually, providing a comprehensive summary of new developments in the technical and commercial areas as well as interpretation of these developments and their impact on the industry. Discussion content includes analysis of key new patents, joint venture developments, commercial developments and announcements, technology advancements, processing breakthroughs, and interviews with key developers and end-users. Reports are between 60-80 pages in length.
  
  
• A full year's subscription to a confidential monthly newsletter entitled "The BioPharma Review" which will contain original industry interviews, Special Feature analysis of scientific positions and commercial developments, as well as announcements relevant to key decision making.
  
  
• Fax/email service for immediate relay of critically important news releases as they happen.

View a sample copy of The BioPharma Review newsletter (requires Acrobat Reader).